Drug profile · INN
radium ra-223 dichloride
XOFIGO
radium ra-223 dichloride (XOFIGO) is a radiotherapy agent. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — radium ra-223 dichloride
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
radium ra-223 dichloride (XOFIGO) is a radiotherapy agent. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Radiotherapy agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is radium ra-223 dichloride?
radium ra-223 dichloride (XOFIGO) is a radiotherapy agent. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for radium ra-223 dichloride?
XOFIGO is a marketed brand name for radium ra-223 dichloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of radium ra-223 dichloride?
radium ra-223 dichloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.